Key result
Dexrazoxane pre-treatment reduces idarubicin-induced DNA damage and lipid peroxidation in HepG2 cells.
Why the study?
Does dexrazoxane reduce idarubicin-induced DNA damage and lipid peroxidation in HepG2 cells?
Does dexrazoxane reduce idarubicin-induced DNA damage and lipid peroxidation in HepG2 cells?
Dexrazoxane attenuates idarubicin-induced DNA damage and lipid peroxidation in HepG2 cells, suggesting potential genoprotective effects alongside its known cardioprotective role.
Does not support changing idarubicin use; leaves open translation of HepG2 effects to clinical cardiotoxicity prevention.
Background: Idarubicin is an anthracycline antibiotic drug widely used in chemotherapy. Dexrazoxane is an iron chelator used clinically against anthracyclines-induced cardiotoxicity. The present study was designed to determine the possible genoprotection of dexrazoxane on idarubicin-induced DNA damage and oxidative stress. Methods: In this study, the induction of DNA damage by idarubicin was examined on HepG2 cells, using comet assay. Cells were exposed to different concentrations of idarubicin in order to find the minimum and suitable genotoxic concentration. To survey the genoprotective effects of dexrazoxane, cells were subjected to several safe concentrations of dexrazoxane (10, 50, 100, and 200 µM) for 24 hours followed by 1 hour exposure to established genotoxic concentration of idarubicin (0.05 µM). Lipid peroxidation was assessed as a biomarker to show the index of oxidative stress and a possible mechanism underlying this amelioration. Results: Dexrazoxane pre-treatment significantly reduced different parameters of DNA migration such as tail length, % DNA in tail, and tail moment. Moreover, the treatment of dexrazoxane (200 µM) decreased the severity of idarubicin-induced lipid peroxidation. Conclusions: Dexrazoxane in addition to cardioprotection against idarubicin-induced cardiotoxicity has the potential to attenuate its DNA damage and lipid peroxidation in normal cells of patients with cancer treated with idarubicin.
No takes yet. Share an insight, caveat, or question.
Zarifi et al. (2018) studied Idarubicin-induced DNA damage and oxidative stress. Dexrazoxane vs. Idarubicin alone was evaluated on DNA damage (tail length, % DNA in tail, and tail moment) and lipid peroxidation. Dexrazoxane pre-treatment significantly reduced idarubicin-induced DNA migration parameters and lipid peroxidation in HepG2 cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: